AVXL250117C16000
- 0.97
- +0.50+106.38%
Anavex Life Sciences Newsroom
10 Health Care Stocks With Whale Alerts In Today's Session
Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday
H.C. Wainwright Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Raises Target Price to $42
Anavex Life Sciences: Buy Rating Driven by European Approval Prospects and Strong Financial Position
Express News | Anavex Life Sciences Corp. : H.c. Wainwright Raises Target Price to $42 From $40
We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn
Anavex Life Sciences Faces Manufacturing Challenges Impacting Product Launch and Financial Stability
Greenfire Resources, Hut 8, TeraWulf, MicroStrategy And Other Big Stocks Moving Higher On Tuesday
Anavex (AVXL.US) is bullish: the new drug application for Alzheimer's disease has been accepted by the EU.
According to Zhito Finance APP, Biotechnology company Anavex Life Sciences (AVXL.US) saw its stock price rise by 30% on Monday, after the company released its third-quarter Earnings Reports and announced that EU regulators have accepted its marketing application for the Alzheimer's candidate drug blarcamesine.
Anavex Life Sciences | 10-K: FY2024 Annual Report
Anavex Stock Rallies 30% on Business Updates
Anavex Life Sciences Up Over 29%, on Pace for Largest Percent Increase Since December 2022 -- Data Talk
Earnings Call Summary | Anavex Life Sciences(AVXL.US) Q4 2024 Earnings Conference
Honda Motor, Rumble, Despegar.com And Other Big Stocks Moving Higher On Monday
D. Boral Capital Maintains Buy on Anavex Life Sciences, Maintains $46 Price Target
Anavex Life Sciences Analyst Ratings
Anavex Life Sciences' Loss Widens on Higher Costs
Anavex Life Sciences Anticipates a Current Cash Utilization Rate Runway of Around Four Years>AVXL
Anavex Life Sciences: Cash and Cash Equivalents of $132.2M at Sept 30 >AVXL
Anavex Life Sciences Q4 2024 GAAP EPS $(0.14) Beats $(0.16) Estimate; Cash Of $132.2M